The 1-year OS in the NUP98 rearrangement, MLL rearrangement/MLL-PTD, fusion gene negative, core binding factor AML and DEK::CAN groups were 100%, 83.3% (95% CI, 46.5–100%), 79.6 (95%CI, 49.9–97.7%), 66.7% (95%CI,14.4–99.8%) and 50.0% (95%CI, 0.9–99.2%) (p = 0.574), respectively. Here, KMT2A is linked to acute myeloid leukemia.